408 related articles for article (PubMed ID: 25019486)
21. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of nerve growth factor in detrusor overactivity: a study on women with mixed urinary incontinence.
Salehi-Pourmehr H; Ghojazadeh M; Jahantabi E; Hajebrahimi S
Int Urol Nephrol; 2021 Aug; 53(8):1557-1562. PubMed ID: 33866484
[TBL] [Abstract][Full Text] [Related]
23. Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men.
Nguyen LN; Bartley J; Killinger KA; Gupta P; Lavin J; Khourdaji A; Gilleran J; Gaines N; Boura JA; Peters KM
Int Urol Nephrol; 2018 May; 50(5):825-832. PubMed ID: 29532309
[TBL] [Abstract][Full Text] [Related]
24. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
Liu HT; Kuo HC
Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
[TBL] [Abstract][Full Text] [Related]
25. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
[TBL] [Abstract][Full Text] [Related]
26. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Thiery E
Urology; 2016 Aug; 94():57-63. PubMed ID: 27131966
[TBL] [Abstract][Full Text] [Related]
27. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol.
Yoong W; Ridout AE; Damodaram M; Dadswell R
BJU Int; 2010 Dec; 106(11):1673-6. PubMed ID: 20590544
[TBL] [Abstract][Full Text] [Related]
28. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
[TBL] [Abstract][Full Text] [Related]
29. Increased urinary nerve growth factor as a predictor of persistent detrusor overactivity after bladder outlet obstruction relief in a rat model.
Lee SR; Hong CH; Choi YD; Kim JH
J Urol; 2010 Jun; 183(6):2440-4. PubMed ID: 20403616
[TBL] [Abstract][Full Text] [Related]
30. The role of electrical stimulation techniques in the management of the male patient with urgency incontinence.
Johnsen NV; Osborn DJ; Dmochowski RR
Curr Opin Urol; 2014 Nov; 24(6):560-5. PubMed ID: 25144143
[TBL] [Abstract][Full Text] [Related]
31. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
Hoda MR; Fornara P
Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
[TBL] [Abstract][Full Text] [Related]
32. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder.
Antunes-Lopes T; Pinto R; Barros SC; Botelho F; Silva CM; Cruz CD; Cruz F
J Urol; 2013 Jan; 189(1):359-65. PubMed ID: 23174241
[TBL] [Abstract][Full Text] [Related]
33. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2008 Nov; 102(10):1440-4. PubMed ID: 18489524
[TBL] [Abstract][Full Text] [Related]
34. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom.
Kim JC; Park EY; Hong SH; Seo SI; Park YH; Hwang TK
Int J Urol; 2005 Oct; 12(10):875-80. PubMed ID: 16323980
[TBL] [Abstract][Full Text] [Related]
35. Intravesical electrical stimulation treatment for overactive bladder: An observational study.
Yune JJ; Shen JK; Pierce MA; Hardesty JS; Kim J; Siddighi S
Investig Clin Urol; 2018 Jul; 59(4):246-251. PubMed ID: 29984339
[TBL] [Abstract][Full Text] [Related]
36. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
37. Sacral nerve stimulation for urinary dysfunction: the first year of the Scottish national service.
Hilmy M; Tatarov O; McQueen L; Small D; Granitsiotis P; Conn IG
Scott Med J; 2012 Nov; 57(4):200-3. PubMed ID: 23138579
[TBL] [Abstract][Full Text] [Related]
38. Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.
Hu H; Zhang W; Liu X; Wang H; Fang Z; Liang C; Wang T; Xu K
J Urol; 2018 Sep; 200(3):620-625. PubMed ID: 29630981
[TBL] [Abstract][Full Text] [Related]
39. Overactive bladder changes with time: a 5-year longitudinal followup of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels.
Chuang FC; Liu HT; Wang LY; Kuo HC
J Urol; 2014 Aug; 192(2):458-63. PubMed ID: 24594404
[TBL] [Abstract][Full Text] [Related]
40. A single-blind, randomized controlled trial to evaluate the effectiveness of transcutaneous tibial nerve stimulation (TTNS) in Overactive Bladder symptoms in women responders to percutaneous tibial nerve stimulation (PTNS).
Martin-Garcia M; Crampton J
Physiotherapy; 2019 Dec; 105(4):469-475. PubMed ID: 30862384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
